Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 5756Lung Neoplasms 3723Small Cell Lung Carcinoma 1021Breast Neoplasms 668Neoplasms 615Colorectal Neoplasms 560Melanoma 479Ovarian Neoplasms 435Neoplasm Metastasis 431Pancreatic Neoplasms 386Stomach Neoplasms 332Carcinoma, Renal Cell 312Adenocarcinoma of Lung 309Squamous Cell Carcinoma of Head and Neck 306Head and Neck Neoplasms 294Prostatic Neoplasms 285Mesothelioma, Malignant 281Esophageal Neoplasms 266Mesothelioma 244Colonic Neoplasms 225Brain Neoplasms 217Urinary Bladder Neoplasms 212Triple Negative Breast Neoplasms 211Uterine Cervical Neoplasms 209Endometrial Neoplasms 175Sarcoma 171Carcinoma, Hepatocellular 159NSCLC 136Carcinoma 128Kidney Neoplasms 127

Interventions

pembrolizumab 1patritumab deruxtecan 1Platinum Compounds 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Nonsquamous Non-small Cell Lung Cancer × Thoracic × Clear all
NCT05338970 2025-01-31

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Daiichi Sankyo

Phase 3 Active not recruiting
586 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡